The increasing numbers of cell and gene therapy pipeline candidates, along with a steady growth of new approvals, are stretching manufacturing capacity to its limits.
The increasing numbers of cell and gene therapy pipeline candidates, along with a steady growth of new approvals, are stretching manufacturing capacity to its limits.